Search
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalPibrentasvir is available as an oral combination therapy with [DB13879] under the brand name Mavyret. … Individual NS5A amino acid substitutions that reduced susceptibility to pibrentasvir include M28G or Q30D in a genotype 1a replicon and P32-deletion in a genotype 1b replicon [L940].
Mixtures: MAVİRET 100 MG/40 MG FİLM KAPLI TABLET, 84 ADET, MAVIRET® 100/40 MG TABLETAS RECUBIERTASCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP1A2 InhibitorsPhenyltoloxamine
go.drugbank.com/drugs/DB11160ApprovedPhenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. … Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient.
Mixtures: Dologesic DF, Flextra-650Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approved[DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%). … of hypoestrogenism due to hypogonadism [FDA Label].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesIL15-NK Cell
go.drugbank.com/drugs/DB15725InvestigationalIn particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Umifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational … Its invention is credited to a collaboration between Russian scientists from several research institutes 40-50 years ago, and reports of its chemical synthesis date back to 1993.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesIrofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.
Zinc acetate
go.drugbank.com/drugs/DB14487ApprovedInvestigationalMixtures: DG Anti-Itch, Dg Health Anti ItchLevoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production. … It possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersRimantadine
go.drugbank.com/drugs/DB00478ApprovedAn RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.
Categories: Influenza A M2 Protein Inhibitor, M2 Protein InhibitorsAminopterin
go.drugbank.com/drugs/DB08878ApprovedWithdrawnAminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. … In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis.